98%
921
2 minutes
20
Importance: Clinical risk algorithms inform clinical decision support and system-level quality metrics. However, algorithm performance can drift over time and possibly promote misinformed decision-making and resource allocation. The Veterans Health Administration (VA) Care Assessment Needs (CAN) algorithm is a nationally deployed population risk algorithm used to predict risk of 90-day hospitalization and/or mortality and to allocate resources for more than 5 million veterans annually. However, drift affecting the VA CAN has not been assessed.
Objective: To evaluate the impact of drift in the VA CAN algorithm and the extent, mechanisms, and clinical consequences of performance changes.
Design, Setting, And Participants: This was a retrospective cohort study using electronic health records (EHRs) and administrative data from the VA Corporate Data Warehouse, which contains observations from more than 5 million veterans per study year. The data comprised 27 787 152 observations among 7 215 711 unique veterans receiving VA primary care from 2016 to 2021. Data analysis was performed from January 2023 and December 2024.
Main Outcomes And Measures: Two primary outcomes were change in model performance (true positive rate [TPR], false positive rate [FPR], positive predictive value [PPV], negative predictive value [NPV], F1 score, and accuracy); and a national quality metric (% of veterans with CAN ≥90th percentile with a palliative care visit).
Results: The study population included 7 215 711 eligible veterans, with a mean (SD) age of 62.1 (16.5); 91.2% were male and 18.2% were Black, 6.6% Hispanic, and 76.2% White individuals. From 2016 to 2021, PPV decreased by 4.0% (95% CI, -2.8% to -5.1%); F1 score decreased by 4.6% (95% CI, -6.1% to 3.0%); NPV increased by 0.43% (95% CI, 0.30% to 0.57%); and FPR increased by 0.34% (95% CI, 0.10% to 0.58%), which corresponds with 18 288 increased false positive results. TPR and accuracy remained stable. The 90-day hospitalization and/or death rates decreased from 3.8% in 2017 to 3.0% in 2021. Covariate shifts were observed in 19 covariates, with demographic characteristics, health care utilization, and laboratory covariates exhibiting the largest shifts. The palliative care quality metric was 2.9% (95% CI, 2.8% to 2.9%) in 2018, 2.6% (95% CI, 2.6% to 2.7%) in 2019, and 2.8% (95% CI, 2.7% to 2.8%) in 2020, with FPRs among metric-eligible veterans increasing from 81.6% (95% CI, 81.5% to 81.7%) in 2018 to 85.7% (95% CI, 85.6% to 85.8%) in 2020.
Conclusions And Relevance: This cohort study found that CAN algorithm performance declined from 2016 to 2021 due to shifts in outcome prevalence and distributions of health care utilization and demographic covariates. Close surveillance of clinical risk algorithms and quality metrics derived from algorithm-generated risk scores could mitigate suboptimal resource allocation or decision-making.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357188 | PMC |
http://dx.doi.org/10.1001/jamahealthforum.2025.2717 | DOI Listing |
Eur Geriatr Med
September 2025
School of Public Health Sciences, University of Waterloo, Waterloo, Canada.
Purpose: Sleep disturbance is prevalent in long-term care facilities (LTCFs), yet there is limited understanding of individual factors predicting changes in sleep within these populations. Our objective was to determine predictors of sleep disturbance in LTCFs and investigate variation in prevalence across facilities in two Canadian provinces-New Brunswick and Saskatchewan.
Method: This retrospective longitudinal cohort study used interRAI comprehensive health assessment data from 2016 to 2021, encompassing 21,394 older adults aged ≥ 65 years across 228 LTCFs.
Ann Surg Oncol
September 2025
Section of Surgical Oncology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Background: Postmastectomy autologous reconstruction (PMAR) is an important component of comprehensive breast cancer care. Previous research has suggested the existence of sociodemographic disparities in complications after immediate PMAR. The objective of this study was to examine the impact of sociodemographic and clinical factors on immediate PMAR postoperative outcomes.
View Article and Find Full Text PDFMicrob Genom
September 2025
Regional Innovative Public Health Laboratory, Rush University Medical Center, Chicago, IL 60612, USA.
emerged in Chicago, IL, USA, in 2016 and has since become endemic. We used whole-genome sequencing (WGS) of 494 isolates, epidemiologic metadata and patient transfer data to describe the transmission of among Chicago healthcare facilities between 2016 and 2021. In total, 99% of isolates formed a single clade IV phylogenetic lineage, suggesting a single introduction.
View Article and Find Full Text PDFJTO Clin Res Rep
October 2025
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
Introduction: Immune checkpoint blockade (ICB) is a standard first-line treatment for stage IV NSCLC without actionable oncogenic alterations. mutations, prevalent in 30% to 40% lung adenocarcinomas (LUAD) in Western populations, currently lack targeted first-line therapies. This study aimed to assess the predictive value of mutations for clinical outcomes after distinct ICB regimens, validating our previous findings in a larger cohort with extended follow-up.
View Article and Find Full Text PDFBr J Dermatol
September 2025
National Disease Registration Service, Data and Analytics, NHS England, Leeds, UK.
Introduction: Skin cancers primarily affect people of White ethnicity and lighter skin tones, but people of other ethnicities may face diagnostic delays and experience higher mortality, reflecting existing inequities in healthcare. This is the first study showing incidence data from the National Disease Registration Service (NDRS) cancer registry in England for skin cancers stratified by the seven broad ethnic groups.
Methods: We used data from NDRS from 2013-20 to analyse melanoma, acral lentiginous melanoma (ALM), basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), cutaneous T-cell lymphoma (CTCL), and Kaposi sarcoma (KS).